Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 831 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research... May 9, 2023 How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist February 23, 2021 ESMO Open: First Official Impact Factor of 5.329 June 30, 2020 ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology... June 19, 2026 Load more HOT NEWS ESMO Responds to Public Consultation on EU4Health Work Programme for 2027... Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO...
